After surveying 30 Biomet-specific orthopedic surgeons who experienced some supply shortages since Q3 of 2016, Citi analyst Amit Hazan sees a higher probability that Zimmer Biomet (ZBH) returns to full supply by end of the summer and begins to regain lost market share. The survey also showed that about half of Zimmer's supply-related share loss has gone to Stryker (SYK), Hazan tells investors in a research note. With the share gains expected to reverse, the analyst expects Stryker's U.S. knee growth to slow in the second half of 2017. He notes consensus expectations have the company's knee growth accelerating in the back half of the year due to MAKO. Hazan raised his price target for Stryker to $125 from $114 citing higher group valuations but keeps a Sell rating on the shares. To reflect an improved outlook, the analyst raised his price target for Zimmer to $130 from $108. He keeps a Neutral rating on the shares.